Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos 
Want to cut your energy bills? Here’s how five experts are doing it 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
MENLO PARK, Calif., March 01, 2017 -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting form of recombinant human growth hormone (rhGH) for growth hormone deficiency (GHD), today announced that the Company is scheduled to present at two upcoming investor conferences. Details are as follows:
| Event: | Cowen & Co. 37th Annual Healthcare Conference |
| Date: | Tuesday, March 7, 2017 |
| Time: | 10:40 a.m. ET |
| Location: | The Boston Marriott Copley Place – Boston, MA |
| Event: | Barclays Global Healthcare Conference |
| Date: | Tuesday, March 14, 2017 |
| Time: | 3:50 p.m. ET |
| Location: | Loews Miami Beach Hotel – Miami, FL |
Audio webcasts of the Company’s presentations will be available on the investor relations section of the Versartis’ website at www.versartis.com. A replay of the presentation will be available for 90 days.
About Versartis, Inc.
Versartis, Inc. is an endocrine-focused biopharmaceutical company initially developing somavaratan, a novel, long-acting form of recombinant human growth hormone in late-stage clinical trials for the treatment of GHD in children and adults. Somavaratan is intended to reduce the burden of daily injection therapy by requiring significantly fewer injections, potentially improving adherence and, therefore, treatment outcomes. For more information on Versartis, visit www.versartis.com.
Contacts: Corporate Communications: Christine Labaree Corporate Affairs (650) 600-1697 [email protected] Investors: David Burke Director, Investor Relations (650) 516-2703 [email protected]
